{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:30:22Z","timestamp":1788618622895,"version":"build-2803163510"},"reference-count":223,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T00:00:00Z","timestamp":1718496000000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U2C CA252981"],"award-info":[{"award-number":["U2C CA252981"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011912","name":"Washington University School of Medicine in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["R35 GM142710"],"award-info":[{"award-number":["R35 GM142710"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009340","name":"Children's Discovery Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007268","name":"Washington University in St Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.semradonc.2023.03.004","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T18:29:56Z","timestamp":1686940196000},"page":"262-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology"],"prefix":"10.1016","volume":"33","author":[{"given":"Noah","family":"Earland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Semenkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep S.","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose P.","family":"Zevallos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadel A.","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2023.03.004_bib0001","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/1878-0261.12659","article-title":"Technology-driven research for radiotherapy innovation","volume":"14","author":"Fiorino","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0002","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.ijrobp.2009.03.059","article-title":"Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensity-modulated radiotherapy: A prospective study","volume":"76","author":"Den","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0003","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semradonc.2011.09.001","article-title":"Image-guided radiotherapy: Has it influenced patient outcomes?","volume":"22","author":"Bujold","year":"2012","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0004","first-page":"686","article-title":"MRI-linear accelerator radiotherapy systems","volume":"30","author":"Liney","year":"2018","journal-title":"Clinicaloncology"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0005","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.semradonc.2014.02.008","article-title":"The ViewRay system: Magnetic resonance\u2013guided and controlled radiotherapy","volume":"24","author":"Mutic","year":"2014","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0006","first-page":"106","article-title":"The technical design and concept of a PET\/CT linac for biology-guided radiotherapy","volume":"29","author":"Oderinde","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0007","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.semradonc.2019.05.006","article-title":"Use of Big Data for quality assurance in radiation therapy","volume":"29","author":"McNutt","year":"2019","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0008","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: The bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0009","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.canlet.2019.12.004","article-title":"Developing more sensitive genomic approaches to detect radioresponse in precision radiation oncology: From tissue DNA analysis to circulating tumor DNA","volume":"472","author":"He","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0010","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S1470-2045(17)30263-2","article-title":"Genomic biomarkers for precision radiation medicine","volume":"18","author":"Bratman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0011","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fonc.2017.00083","article-title":"Data-based radiation oncology: Design of clinical trials in the toxicity biomarkers era","volume":"7","author":"Azria","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0012","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.semradonc.2017.04.005","article-title":"Radiogenomics: Identification of genomic predictors for radiation toxicity","volume":"27","author":"Rosenstein","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41571-022-00660-y","article-title":"Circulating tumour DNA: Looking beyond the blood","volume":"19","author":"Tivey","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0014","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1002\/cncr.26729","article-title":"Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy","volume":"118","author":"Zafarana","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0015","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/ijc.32793","article-title":"Decreased local immune response and retained HPV gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer","volume":"146","author":"Cosper","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0016","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41591-019-0595-z","article-title":"A clonal expression biomarker associates with lung cancer mortality","volume":"25","author":"Biswas","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0017","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-019-0592-2","article-title":"Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer","volume":"25","author":"Joshi","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0018","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non\u2013small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0019","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40291-019-00390-5","article-title":"Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA)","volume":"23","author":"Chin","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0021","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: Circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105776","article-title":"The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma","volume":"126","author":"Haring","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0023","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0024","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1038\/s41467-018-07466-6","article-title":"Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease","volume":"9","author":"Moss","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","article-title":"Sensitive tumour detection and classification using plasma cell-free DNA methylomes","volume":"563","author":"Shen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0026","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0027","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0028","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.21.01929","article-title":"Circulating tumor DNA minimal residual disease detection of non\u2013small-cell lung cancer treated with curative intent","volume":"40","author":"Pellini","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0029","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0030","first-page":"1","article-title":"Detection and diagnostic utilization of cellular and cell-free tumor DNA","volume":"16","author":"Dudley","year":"2020","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0031","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0032","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-018-0058-3","article-title":"Early stage NSCLC\u2014Challenges to implementing ctDNA-based screening and MRD detection","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0034","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0035","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40291-021-00559-x","article-title":"Commercial ctDNA assays for minimal residual disease detection of solid tumors","volume":"25","author":"Chen","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0037","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers14122968","article-title":"The promise of circulating tumor DNA in head and neck cancer","volume":"14","author":"Aulakh","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0038","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-21-0110","article-title":"Tumor-na\u00efve multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma","volume":"27","author":"Burgener","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0039","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1158\/1078-0432.CCR-14-2594","article-title":"Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy","volume":"21","author":"Mok","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease\u2014Latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0041","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1002\/cam4.4726","article-title":"Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma","volume":"11","author":"Kogo","year":"2022","journal-title":"Cancer Med US"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0042","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0043","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/PO.20.00276","article-title":"ctDNA MRD detection and personalized oncogenomic analysis in oligometastatic colorectal cancer from plasma and urine","author":"Pellini","year":"2021","journal-title":"Jco Precis Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0044","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0046","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2209852119","article-title":"Epigenetic analysis of cell-free DNA by fragmentomic profiling","volume":"119","author":"Zhou","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0047","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41596-019-0202-2","article-title":"Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA","volume":"14","author":"Shen","year":"2019","journal-title":"Nat Protoc"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0048","doi-asserted-by":"crossref","first-page":"S575","DOI":"10.1016\/j.annonc.2022.07.106","article-title":"73P Multi-cancer early detection through evaluation of aneuploidy, methylation, and protein biomarkers in plasma","volume":"33","author":"Douville","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0049","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1053\/j.gastro.2019.10.039","article-title":"Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer","volume":"158","author":"Azad","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11864-019-0653-2","article-title":"The role of circulating tumor DNA in lung cancer: Mutational analysis, diagnosis, and surveillance now and into the future","volume":"20","author":"Scilla","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0051","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ijrobp.2020.05.008","article-title":"The utility of liquid biopsies in radiation oncology","volume":"107","author":"Michino","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0052","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.semradonc.2015.05.001","article-title":"Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA","volume":"25","author":"Chaudhuri","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0053","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck cancer","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0054","doi-asserted-by":"crossref","first-page":"c4684","DOI":"10.1136\/bmj.c4684","article-title":"Head and neck cancer\u2014Part 1: Epidemiology, presentation, and prevention","volume":"341","author":"Mehanna","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0055","first-page":"296","article-title":"Contemporary management of head and neck cancers","volume":"11","author":"Gil","year":"2009","journal-title":"Israel Med Assoc J"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0056","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oraloncology.2011.03.009","article-title":"A meta-analysis of the randomized controlled trials on elective neck dissection versus therapeutic neck dissection in oral cavity cancers with clinically node-negative neck","volume":"47","author":"Fasunla","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0057","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ecl.2008.02.001","article-title":"External beam radiation therapy for thyroid cancer","volume":"37","author":"Brierley","year":"2008","journal-title":"Endocrin Metab Clin"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0058","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.soc.2007.10.014","article-title":"Surgery for thyroid cancer","volume":"17","author":"Gil","year":"2008","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0059","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ijrobp.2005.09.041","article-title":"French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin\/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC)","volume":"64","author":"Bensadoun","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0060","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2005.07.010","volume":"23","author":"Budach","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0061","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1056\/NEJM199806183382503","article-title":"Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer","volume":"338","author":"Brizel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0062","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/COC.0b013e3181942a3b","article-title":"Pretreatment prognostic factors influencing distant metastasis-free survival in locally advanced squamous cell carcinoma of the head and neck treated with radiation therapy with or without concurrent chemotherapy","volume":"32","author":"Jeremi","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0063","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0064","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0065","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0066","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.semradonc.2021.04.001","article-title":"Epidemiology of HPV related malignancies","volume":"31","author":"Scott-Wittenborn","year":"2021","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0067","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.oraloncology.2016.08.019","article-title":"Prognostic significance of non-HPV16 genotypes in oropharyngeal squamous cell carcinoma","volume":"61","author":"Mazul","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0068","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.ejca.2015.09.005","article-title":"Human papillomavirus genotype and oropharynx cancer survival in the United States of America","volume":"51","author":"Goodman","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0069","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fonc.2019.00682","article-title":"Papillomavirus immune evasion strategies target the infected cell and the local immune system","volume":"9","author":"Zhou","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0070","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.18632\/oncotarget.27992","article-title":"Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"12","author":"Haring","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0071","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jamaoto.2014.1338","article-title":"Saliva and plasma quantitative polymerase chain reaction\u2013based detection and surveillance of human papillomavirus\u2013related head and neck cancer","volume":"140","author":"Ahn","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0072","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaoncol.2019.0439","article-title":"Association of oral human papillomavirus DNA persistence with cancer progression after primary treatment for oral cavity and oropharyngeal squamous cell carcinoma","volume":"5","author":"Fakhry","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0073","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.ejso.2022.03.232","article-title":"Longitudinal measurement of HPV copy number in cell-free DNA is associated with patient outcomes in HPV-positive oropharyngeal cancer","volume":"48","author":"Warlow","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0074","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0075","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0076","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1078-0432.CCR-21-3151","article-title":"Cell-free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer cell-free HPV DNA for HPV-associated head and neck cancer","volume":"28","author":"Siravegna","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0077","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.oraloncology.2019.06.019","article-title":"Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer","volume":"95","author":"Hanna","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0078","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/path.5249","article-title":"Plasma Epstein\u2013Barr virus DNA as an archetypal circulating tumour DNA marker","volume":"247","author":"Lam","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25011\/cim.v40i1.28049","article-title":"Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis","volume":"40","author":"Liu","year":"2017","journal-title":"Clin Investig Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0080","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1158\/1078-0432.CCR-05-0648","article-title":"A comparison study of different PCR assays in measuring circulating plasma Epstein-Barr Virus DNA levels in patients with nasopharyngeal carcinoma","volume":"11","author":"Le","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0081","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0082","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein\u2013Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Allen","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0083","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3892\/ol.2015.3628","article-title":"Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma","volume":"10","author":"Zhao","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0084","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2019.01.007","article-title":"Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma","volume":"104","author":"Huang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0085","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/annonc\/mdu117","article-title":"Plasma Epstein\u2013Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma","volume":"25","author":"Leung","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0086","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein\u2013Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0087","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0088","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1126\/science.1208130","article-title":"The mutational landscape of head and neck squamous cell carcinoma","volume":"333","author":"Stransky","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0089","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrc.2018.11","article-title":"The molecular landscape of head and neck cancer","volume":"18","author":"Leemans","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0090","first-page":"1548","article-title":"Gene mutations in circulating tumour DNA as a diagnostic and prognostic marker in head and neck cancer\u2014A systematic review","volume":"9","author":"Hude\u010dkov\u00e1","year":"2021","journal-title":"Biomed"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104852","article-title":"Comprehensive multiparameter genetic analysis improves circulating tumor DNA detection in head and neck cancer patients","volume":"109","author":"Mes","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0092","doi-asserted-by":"crossref","first-page":"293ra104","DOI":"10.1126\/scitranslmed.aaa8507","article-title":"Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas","volume":"7","author":"Wang","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0093","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41416-022-01716-7","article-title":"Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)\u2014A personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma","volume":"126","author":"Flach","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0094","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1200\/JCO.19.02748","article-title":"Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline","volume":"38","author":"Schneider","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0095","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0096","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non\u2013small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0097","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semradonc.2023.03.004_bib0098","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0099","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/2159-8290.CD-16-0127","article-title":"Role of KEAP1\/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance","volume":"7","author":"Jeong","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0100","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2017.06.021","article-title":"Circulating tumor DNA analysis during radiation therapy for localized lung cancer predicts treatment outcome","volume":"99","author":"Chaudhuri","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0101","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1016\/j.ijrobp.2019.06.610","article-title":"Circulating tumor DNA changes during chemoradiation for lung cancer predict patient outcomes","volume":"105","author":"Moding","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0102","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fonc.2019.00208","article-title":"A review on the special radiotherapy techniques of colorectal cancer","volume":"9","author":"Tam","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0103","first-page":"329","article-title":"Treatment of colorectal cancer: surgery, chemotherapy and radiotherapy","volume":"26","author":"Simpson","year":"2008","journal-title":"Surg Oxf"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0104","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0105","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semradonc.2023.03.004_bib0106","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1200\/JCO.2005.08.144","article-title":"Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate","volume":"23","author":"Folkesson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003741","article-title":"Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study","volume":"18","author":"Wang","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0108","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/gutjnl-2017-315852","article-title":"Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: A prospective biomarker study","volume":"68","author":"Tie","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0109","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/codi.13081","article-title":"Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A systematic review","volume":"17","author":"Ryan","year":"2015","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0110","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0111","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"Sausen","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0112","doi-asserted-by":"crossref","first-page":"10202","DOI":"10.1073\/pnas.1704961114","article-title":"Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers","volume":"114","author":"Cohen","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0113","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0114","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"Ca Cancer J Clin"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0115","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0116","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0117","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bju.14636","article-title":"Examining the relationship between complications and perioperative mortality following radical cystectomy: A population-based analysis","volume":"124","author":"Mossanen","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0118","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.currproblcancer.2014.06.001","article-title":"Multimodal management of muscle-invasive bladder cancer","volume":"38","author":"Park","year":"2014","journal-title":"Curr Prob Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0119","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: An updated analysis of the Massachusetts general hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0120","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: A pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0121","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0122","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1756287211407543","article-title":"Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy","volume":"3","author":"Balar","year":"2011","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0123","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.euf.2016.12.005","article-title":"Absence of tumor on repeat transurethral resection of bladder tumor does not predict final pathologic T0 stage in bladder cancer treated with radical cystectomy","volume":"4","author":"Kukreja","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0124","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0125","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: What are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0126","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S1470-2045(18)30693-4","article-title":"Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer","volume":"19","author":"Miyamoto","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0127","doi-asserted-by":"crossref","first-page":"IA25","DOI":"10.1158\/1557-3265.BLADDER19-IA25","article-title":"Abstract IA25: Molecular biomarkers of chemoradiation response in bladder preservation therapy","volume":"26","author":"Miyamoto","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0128","doi-asserted-by":"crossref","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Sethi H, et al: Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma, J Clin Oncol, 37:1547-1557, 2019, In press, https:\/\/doi.org\/10.1200\/jco.18.02052.","DOI":"10.1200\/JCO.18.02052"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0129","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0130","article-title":"Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study","volume":"18","author":"Chauhan","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib222","doi-asserted-by":"crossref","unstructured":"Chauhan PS, Shiang A, Alahi I, et al: Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients, NPJ Precis Oncol, 7:1\u20136, 2023.","DOI":"10.1038\/s41698-022-00345-w"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0131","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0132","doi-asserted-by":"crossref","unstructured":"Hennigan ST, Trostel SY, Terrigino NT, et al: Low abundance of circulating tumor DNA in localized prostate cancer, JCO Precis Oncol, 3:1-132019,","DOI":"10.1200\/PO.19.00176"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0133","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13073-020-00770-1","article-title":"Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression","volume":"12","author":"Lau","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0134","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1038\/s41467-022-34012-2","article-title":"The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0135","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0136","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13014-016-0586-x","article-title":"[18F]Choline PET\/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: Preliminary results","volume":"11","author":"Pasqualetti","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0137","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0138","doi-asserted-by":"crossref","unstructured":"Ost P, Reynders D, Decaestecker K, et al: Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36:2018 In press, https:\/\/doi.org\/10.1200\/jco.2017.75.4853.","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0139","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0140","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","article-title":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","volume":"7","author":"Quigley","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0141","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0143","first-page":"200","article-title":"Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine","volume":"70","author":"Gamboa","year":"2020","journal-title":"Ca Cancer J Clin"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0144","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1996.14.3.859","article-title":"Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma","volume":"14","author":"Pisters","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0145","first-page":"1315","article-title":"Liquid biopsies in sarcoma clinical practice: Where do we stand?","volume":"9","author":"van der Laan","year":"2021","journal-title":"Biomed"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0146","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0147","doi-asserted-by":"crossref","first-page":"E5564","DOI":"10.1073\/pnas.1419260111","article-title":"Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma","volume":"111","author":"Perry","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003734","article-title":"Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study","volume":"18","author":"Szymanski","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib223","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1158\/1078-0432.CCR-17-3704","article-title":"Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma","volume":"24","author":"Przybyl","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0150","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1002\/cncr.30144","article-title":"Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA","volume":"122","author":"Hayashi","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0151","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1158\/1078-0432.CCR-15-3028","article-title":"Genomic EWSR1 fusion sequence as highly sensitive and dynamic plasma tumor marker in Ewing sarcoma","volume":"22","author":"Krumbholz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00285","article-title":"Detection of somatic structural variants enables quantification and characterization of circulating tumor DNA in children with solid tumors","volume":"2018","author":"Klega","year":"2018","journal-title":"Jco Precis Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0153","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/1535-7163.MCT-20-0987","article-title":"A comprehensive circulating tumor DNA assay for detection of translocation and copy-number changes in pediatric sarcomas","volume":"20","author":"Shah","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0154","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.21037\/tcr.2019.12.70","article-title":"Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients","volume":"9","author":"Porter","year":"2020","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0156","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/cncr.28964","article-title":"Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non\u2013small cell lung cancer during treatment with erlotinib","volume":"120","author":"Sorensen","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0157","doi-asserted-by":"crossref","first-page":"42988","DOI":"10.18632\/oncotarget.8943","article-title":"Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma","volume":"7","author":"Braig","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0158","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","article-title":"Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors","volume":"8","author":"Bai","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0159","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40364-022-00378-0","article-title":"The role of biomarkers in personalized immunotherapy","volume":"10","author":"Sankar","year":"2022","journal-title":"Biomark Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0160","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","article-title":"Atlas of clinically distinct cell states and ecosystems across human solid tumors","volume":"184","author":"Luca","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0161","doi-asserted-by":"crossref","first-page":"10312","DOI":"10.18632\/oncotarget.14400","article-title":"Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM","volume":"8","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0162","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41416-021-01438-2","article-title":"TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma","volume":"125","author":"Casey","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0163","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-11-2260","article-title":"TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence","volume":"18","author":"Skinner","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0164","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SLA.0b013e31822b8cfa","article-title":"Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer","volume":"254","author":"Garcia-Aguilar","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cllc.2014.09.005","article-title":"Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non\u2013small-cell lung cancer","volume":"16","author":"Mak","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0166","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/2159-8290.CD-20-0282","article-title":"KEAP1\/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition","volume":"10","author":"Binkley","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0167","doi-asserted-by":"crossref","first-page":"e1284","DOI":"10.1097\/MD.0000000000001284","article-title":"KRAS mutation status is not a predictor for tumor response and survival in rectal cancer patients who received preoperative radiotherapy with 5-fluoropyrimidine followed by curative surgery","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0168","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/bbrc.1997.6943","article-title":"An Nrf2\/Small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements","volume":"236","author":"Itoh","year":"1997","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0169","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1038\/ncomms11428","article-title":"A genetic basis for the variation in the vulnerability of cancer to DNA damage","volume":"7","author":"Yard","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0170","first-page":"1","article-title":"Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade","author":"Spurr","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0171","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s42003-021-01657-6","article-title":"Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer","volume":"4","author":"Jia","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0172","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(16)30648-9","article-title":"A genome-based model for adjusting radiotherapy dose (GARD): A retrospective, cohort-based study","volume":"18","author":"Scott","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0173","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(21)00347-8","article-title":"Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): A cohort-based pooled analysis","volume":"22","author":"Scott","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0174","doi-asserted-by":"crossref","unstructured":"Price JM, Prabhakaran A, West CML: Predicting tumour radiosensitivity to deliver precision radiotherapy, Nat Rev Clin Oncol, 20:1\u201316, 2022","DOI":"10.1038\/s41571-022-00709-y"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0175","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ijrobp.2009.06.014","article-title":"A gene expression model of intrinsic tumor radiosensitivity: Prediction of response and prognosis after chemoradiation","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0176","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0177","doi-asserted-by":"crossref","first-page":"12003","DOI":"10.1200\/JCO.2018.36.15_suppl.12003","article-title":"Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study","volume":"36","author":"Swanton","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib224","doi-asserted-by":"crossref","unstructured":"Hu Y, Ulrich BC, et al: False-Positive Plasma Genotyping Due to Clonal Hematopoiesis, Clinical Cancer Research, 24:4437\u20134443, 2018","DOI":"10.1158\/1078-0432.CCR-18-0143"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0178","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0179","first-page":"102","article-title":"Role of FSH in male gonadal function","volume":"60","author":"Simoni","year":"1999","journal-title":"Ann D'endocrinol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0180","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.radonc.2013.05.001","article-title":"Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer","volume":"107","author":"Kerns","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0181","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.juro.2013.01.096","article-title":"A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer","volume":"190","author":"Kerns","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0182","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebiom.2016.07.022","article-title":"Meta-analysis of genome wide association studies identifies genetic markers of late toxicity following radiotherapy for prostate cancer","volume":"10","author":"Kerns","year":"2016","journal-title":"Ebiomedicine"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0183","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/bjc.2012.290","article-title":"A replicated association between polymorphisms near TNF\u03b1 and risk for adverse reactions to radiotherapy","volume":"107","author":"Talbot","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0184","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijrobp.2013.02.025","article-title":"SNP in TXNRD2 associated with radiation-induced fibrosis: A study of genetic variation in reactive oxygen species metabolism and signaling","volume":"86","author":"Edvardsen","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0185","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2015.04.011","article-title":"XRCC1 polymorphism associated with late toxicity after radiation therapy in breast cancer patients","volume":"92","author":"Seibold","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0186","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.radonc.2016.06.017","article-title":"Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients","volume":"121","author":"Andreassen","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0187","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ijrobp.2012.10.011","article-title":"Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer","volume":"85","author":"Pang","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0188","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.radonc.2011.08.039","article-title":"Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio(chemo)therapy","volume":"101","author":"Guerra","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0189","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cps.2009.07.002","article-title":"Complete lymph node dissection for regional nodal metastasis","volume":"37","author":"Dzwierzynski","year":"2010","journal-title":"Clin Plast Surg"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0190","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0191","series-title":"Holland-Frei Cancer Medicine","article-title":"Role of the surgical pathologist in the diagnosis and management of the cancer patient","author":"Connolly","year":"2003"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0192","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","article-title":"Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial","volume":"296","author":"Thompson","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0193","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/j.1464-410X.2011.10572.x","article-title":"High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy","volume":"109","author":"Savdie","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0194","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2008.12.029","article-title":"Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma","volume":"113","author":"Cannon","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0195","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/hed.24824","article-title":"Impact of positive margins on outcomes of oropharyngeal squamous cell carcinoma according to p16 status","volume":"39","author":"Molony","year":"2017","journal-title":"Head Amp Neck"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0196","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1245\/s10434-020-08217-y","article-title":"Surgical margins and adjuvant therapies in malignant phyllodes tumors of the breast: A multicenter retrospective study","volume":"27","author":"Neron","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0197","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/1752-1947-8-460","article-title":"Anaplastic transformation of papillary thyroid carcinoma in multiple lung metastases presenting with a malignant pleural effusion: a case report","volume":"8","author":"Abe","year":"2014","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0198","doi-asserted-by":"crossref","first-page":"e17627","DOI":"10.1097\/MD.0000000000017627","article-title":"Outcomes of pathologically localized high-grade prostate cancer treated with radical prostatectomy","volume":"98","author":"Heo","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0199","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4143\/crt.2004.36.2.121","article-title":"Impact of the new AJCC staging system and adjuvant treatment in rectal cancer","volume":"36","author":"Lee","year":"2004","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0200","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/EDBK_320939","article-title":"Assessment criteria and clinical implications of extranodal extension in head and neck cancer","volume":"41","author":"Huang","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0201","doi-asserted-by":"crossref","first-page":"9534","DOI":"10.1038\/s41598-021-88716-4","article-title":"Prognostic value of extranodal extension in axillary lymph node-positive breast cancer","volume":"11","author":"Ma","year":"2021","journal-title":"Sci Rep UK"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0202","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0203","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0360-3016(99)00169-8","article-title":"The efficacy of early adjuvant radiation therapy for pt3n0 prostate cancer: A matched-pair analysis","volume":"45","author":"Valicenti","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0204","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s12149-021-01663-y","article-title":"Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer","volume":"35","author":"Ledwon","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/RLU.0b013e318203bb84","article-title":"Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan","volume":"36","author":"Giovanella","year":"2011","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0206","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1210\/jc.2011-1740","article-title":"Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)","volume":"96","author":"Spencer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0207","first-page":"125","article-title":"Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification","volume":"78","author":"Ankerst","year":"2006","journal-title":"Arch Ital Urol Androl"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0208","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.3390\/curroncol29050295","article-title":"De-escalation strategies for human papillomavirus-associated oropharyngeal squamous cell carcinoma\u2014Where are we now?","volume":"29","author":"Silver","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0209","doi-asserted-by":"crossref","first-page":"TPS6097","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS6097","article-title":"PATHOS: A phase II\/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer","volume":"36","author":"Evans","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0210","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.19.00463","article-title":"Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus\u2013associated oropharynx squamous cell carcinoma","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0211","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.ijrobp.2021.09.012","article-title":"MC1675, a phase III evaluation of de-escalated adjuvant radiation therapy (DART) vs. standard adjuvant treatment for human papillomavirus associated oropharyngeal squamous cell carcinoma","volume":"111","author":"Ma","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0212","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.02.012","article-title":"Detectable post-operative circulating tumor human papillomavirus (HPV) DNA and association with recurrence in patients with HPV-associated oropharyngeal squamous cell carcinoma","author":"Routman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0213","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.ijrobp.2021.12.108","article-title":"Detection of locoregional minimal residual disease immediately after surgery through multi-omic analysis of tumor-associated cell-free DNA in surgical drain fluid","volume":"112","author":"Earland","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0214","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200496","article-title":"Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: A systematic review and meta-analysis on the current prospective evidence","volume":"93","author":"Yan","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0215","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0216","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0217","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr-21-265","article-title":"Defining oligometastatic non-small cell lung cancer: Concept versus biology, a literature review","author":"Mentink","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0218","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0219","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PPO.0000000000000437","article-title":"Circulating tumor DNA biomarkers for early detection of oligometastasis","volume":"26","author":"Routman","year":"2020","journal-title":"Cancer J"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0220","first-page":"631","volume":"22","author":"Sharabi","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.semradonc.2023.03.004_bib0221","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Victor","year":"2015","journal-title":"Nature"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429623000188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429623000188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:01:17Z","timestamp":1778518877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429623000188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":223,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1053429623000188"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2023.03.004","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2023.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}